Her2 in ovarian tumours

Immunohistochemistry

 

 Reference 1

Her-2

  

negative

faint

moderate

strong

Benign tumours

7

0

0

0

Borderline serous tumours

18

1

0

0

Serous carcinomas

105

15

4

2

Borderline mucinous tumours

9

6

0

1

Mucinous carcinomas

9

1

0

2

Borderline endometrioid tumours

1

0

0

0

Endometrioid carcinomas

17

1

1

1

Clear cell carcinomas

3

1

1

0

Granulosa cell tumours

20

0

0

0

Mixed tumours

8

0

0

0

Carcinosarcomas

5

3

4

1

Total

202

28

10

7
         

Immunoreactivity for Her2 correlates well with FISH analysis of gene amplification1.

There was no correlation of immunoreactivity with tumour type, stage, grade or survival1.

References

1 Mayr D, Kanitz V, Amann G, et al. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 2006; 48:149-56

This page last revised 28.1.2006.

©SMUHT/PW Bishop